Inside Peptides
Search
Menu

WADA Peptide Rules: Prohibited List, Testing & Detection

Athletic & Anti-Doping 12 min read
Executive Summary

The World Anti-Doping Agency (WADA) maintains strict, globally harmonized standards prohibiting performance-enhancing and recovery peptides in competitive sport. Understanding how the Prohibited List categorizes peptides is critical for competitive athletes, sports physicians, and scientific researchers.

Key Safety Takeaways
  • Peptides are prohibited at all times, both In-Competition and Out-of-Competition, under the World Anti-Doping Code.
  • Section S2 bans Peptide Hormones, Growth Factors, and Mimetics (including GHRH analogues, GH secretagogues, and erythropoietins).
  • Section S0 bans Non-Approved Substances: any pharmacological substance without current human regulatory approval is automatically prohibited (including BPC-157 and TB-500).
  • Advanced anti-doping laboratories use High-Resolution Mass Spectrometry (LC-HRMS) to detect intact peptides and long-lived urinary metabolites down to picogram levels.
WADA anti-doping classification diagram illustrating Section S2 peptide hormones, Section S0 unapproved experimental substances, and the strict liability legal framework for tested athletes.
Figure 1: WADA regulatory classification architecture. Peptides are banned at all times under Section S2 (hormones/growth factors) or Section S0 (unapproved substances), with athlete strict liability enforced regardless of intentionality or vendor product labeling.

The WADA Prohibited List Architecture

Peptides fall under two primary sections of the WADA International Standard Prohibited List:

  • Section S2: Peptide Hormones, Growth Factors, Related Substances, and Mimetics: This category explicitly prohibits growth hormone secretagogues (GHRH analogues such as CJC-1295, tesamorelin; ghrelin receptor agonists such as ipamorelin, MK-677; GH-releasing peptides including GHRP-2, GHRP-6, hexarelin), erythropoietin receptor agonists (EPO), and transforming/fibroblast growth factors.
  • Section S0: Non-Approved Substances: A broad catch-all category prohibiting any pharmacological substance not addressed by other sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use. Research compounds are banned at all times whichever section applies: BPC-157 is named as an S0 example, TB-500 is named under S2.3 (thymosin-β4 and its derivatives), AOD-9604 under S2.2.3 (growth hormone fragments) and MOTS-c under S4.4.1 (metabolic modulators).

Anti-Doping Detection & Testing Methodologies

WADA-accredited analytical laboratories employ bioanalytical methods to identify peptide misuse:

  • Immunoaffinity Purification: Magnetic beads coated with targeted anti-peptide antibodies extract trace quantities of peptides from complex urine or plasma matrices.
  • Liquid Chromatography-High Resolution Mass Spectrometry (LC-HRMS): Orbitrap and Q-TOF mass spectrometers identify peptides and their cleaved enzymatic metabolites with sub-ppm mass accuracy.
  • Metabolite Profiling: Because parent peptides are rapidly cleared by systemic endopeptidases within hours, anti-doping scientists characterize long-lived cleavage fragments that remain detectable in urine for days or weeks post-administration.
  • Athlete Biological Passport (ABP): Longitudinal monitoring of endocrine biomarkers (IGF-1, P-III-NP, reticulocyte count) flags indirect physiological evidence of peptide abuse even if the substance itself has cleared.

Sanctions and Athlete Strict Liability

Under Article 2.1 of the World Anti-Doping Code, athletes are strictly responsible for any substance present in their biological samples. Testing positive for an S2 or S0 prohibited peptide carries a standard 4-year period of ineligibility for intentional use, along with forfeiture of competitive titles, prizes, and public sanction.

Scientific & Regulatory References

  1. WADA Prohibited List 2026: International Standard
    World Anti-Doping Agency (WADA) (2026).
    Primary Source
  2. Identification and mass spectrometric characterization of in vitro and in vivo metabolites of BPC-157 for doping control purposes
    Thomas A, et al. (2021) · Drug Testing and Analysis, 13(8):1542-1550.

Regulatory & Health Disclaimer

Inside Peptides provides educational analysis of pharmaceutical standards and biomedical literature. This guide does not constitute medical, legal, or pharmacological advice. Never self-administer unapproved research compounds or alter prescribed treatments without licensed medical oversight.